<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299349</url>
  </required_header>
  <id_info>
    <org_study_id>13055-13-034</org_study_id>
    <nct_id>NCT02299349</nct_id>
  </id_info>
  <brief_title>Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection</brief_title>
  <official_title>Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection in 70 Patients Undergoing Total Knee Arthroplasty Without Femoral Nerve Block: a Double-blinded, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chris Scheuerman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite a robust multimodal pain management regimen, patients undergoing total knee
      arthroplasty (TKA) continue to report low satisfaction with postoperative pain management.
      Patient satisfaction further declines with any adverse event such as a drug reaction to
      neuroleptic medications or a patient fall due to a femoral nerve block. A new method of pain
      management throughout the hospital experience is warranted to improve patient satisfaction
      and the possibility of related adverse events. The purpose of this study is to examine if
      there is a difference in post operative pain and morphine (MSO4) total consumption for
      hospitalized TKA patients without femoral nerve block receiving an intra-operative
      periarticular injection of bupivacaine liposome suspension versus a concentrated multi drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The void in the literature is that while multimodal pain management reduces postoperative
      pain in the majority of TKA patients6-14, too many are still dissatisfied with overall pain
      control13 and adverse drug reactions (dizziness and somnolence) to neuroleptic
      medications15. Additionally, postoperative falls are greater with femoral nerve blocks16,
      and new neurological symptoms are associated with the block17. Bupivacaine liposome
      suspension periarticular injection has large scale national anecdotal support for TKA pain
      control with avoidance of regional block adversity. There is one recent randomized control
      trial in TKA patients favorably comparing periarticular injection with bupivacaine liposome
      suspension versus bupivacaine hydrochloride (HCL)5. To date the clinical use and published
      evidence most robustly supports bupivacaine liposome suspension in patients undergoing
      bunionectomy or hemorrhoidectomy. Additionally, in preparation for shorter hospital stays
      for total joint arthroplasty, a more effective and better tolerated pain management solution
      is needed.

      Hypothesis Statement:

      Hospitalized TKA patients without a pre-operative femoral nerve block will experience
      improved postoperative pain control and less MSO4 equivalence consumption when receiving an
      injection of bupivacaine liposome suspension versus concentrated multi drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain Scores (Visual Analog Pain Scores)</measure>
    <time_frame>1 day following surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>visual analog pain scores (scale 0=no pain; 10=worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MS04 Equivalent Consumption</measure>
    <time_frame>1 day following surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>in hospital total MS04 equivalent consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>bupivacaine liposome suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bupivacaine liposome suspension periarticular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>concentrated multi drug injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concentrated multi drug periarticular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine liposome suspension</intervention_name>
    <description>bupivacaine liposome suspension periarticular injection</description>
    <arm_group_label>bupivacaine liposome suspension</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL</intervention_name>
    <description>Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
    <arm_group_label>concentrated multi drug injection</arm_group_label>
    <other_name>Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TKA candidacy

          -  Osteoarthritis

          -  Failure of non-operative treatments to control knee pain

          -  Patients able to understand and agree to study inclusion

        Exclusion Criteria:

          -  Subjects have orthopaedic and medical co-morbidities that would thwart postoperative
             pain control such as extra-articular pathology with referred pain to the knee (spinal
             stenosis, neuropathy,ipsilateral hip disease)

          -  Severe knee deformity

          -  Post-traumatic and inflammatory arthritis

          -  BMI above 40

          -  Patients unable to receive multimodal pain remitting agents

          -  Active knee sepsis

          -  Remote sites of active infection

          -  Diabetes with A1C &gt; 7

          -  ASA class &gt; lll

          -  Cardiac disease failing medical clearance

          -  Severe liver disease

          -  PAD with AAI &lt; 0.75

          -  Seizure disorder

          -  Allergic to any pain remitting agent

          -  Alcohol abuse

          -  Smoking abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>April 2, 2015</lastchanged_date>
  <firstreceived_date>November 17, 2014</firstreceived_date>
  <firstreceived_results_date>April 2, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine Liposome Suspension</title>
          <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
        </group>
        <group group_id="P2">
          <title>Concentrated Multi Drug Injection</title>
          <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Men and women aged 18 and up receiving total knee arthroplasty for degenerative joint disease</population>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine Liposome Suspension</title>
          <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
        </group>
        <group group_id="B2">
          <title>Concentrated Multi Drug Injection</title>
          <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67.3" spread="10.3"/>
                <measurement group_id="B2" value="65.6" spread="7.9"/>
                <measurement group_id="B3" value="66.4" spread="9.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores (Visual Analog Pain Scores)</title>
        <description>visual analog pain scores (scale 0=no pain; 10=worst pain imaginable)</description>
        <time_frame>1 day following surgery</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Liposome Suspension</title>
            <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
          </group>
          <group group_id="O2">
            <title>Concentrated Multi Drug Injection</title>
            <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Scores (Visual Analog Pain Scores)</title>
            <description>visual analog pain scores (scale 0=no pain; 10=worst pain imaginable)</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.6" spread="1.27"/>
                  <measurement group_id="O2" value="3.3" spread="1.55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MS04 Equivalent Consumption</title>
        <description>in hospital total MS04 equivalent consumption</description>
        <time_frame>1 day following surgery</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Liposome Suspension</title>
            <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
          </group>
          <group group_id="O2">
            <title>Concentrated Multi Drug Injection</title>
            <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>MS04 Equivalent Consumption</title>
            <description>in hospital total MS04 equivalent consumption</description>
            <units>mg</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.0" lower_limit="5.0" upper_limit="15.0"/>
                  <measurement group_id="O2" value="15.0" lower_limit="8.0" upper_limit="20.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine Liposome Suspension</title>
          <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
        </group>
        <group group_id="E2">
          <title>Concentrated Multi Drug Injection</title>
          <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela N Fellner PhD CCRP</name_or_title>
      <organization>TriHealth Hatton Research Institute</organization>
      <phone>513-862-2330</phone>
      <email>Angie_Fellner@trihealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
